You are unique, and so should your treatment be.

To learn more about Selective Internal Radiation Therapy (SIRT) and the unique benefits of our products, visit our patient information website.

Read more
Perform treatment planning with Q-Suite™

Q-Suite™ is software for dosimetric verification of Ho-166 SIRT. A workflow-based user interface makes Q-Suite™ easy to learn and use.

LEARN MORE
Events
Meet us in virtual at CIRCE 2020

The Quirem team will attend the virtual CIRSE summit from September 12th - 16th

Visit the CIRSE website
Events
Meet us in Stockholm at ECIO 2021

The Quirem team will attend ECIO in Stockholm from 11-14 April 2021

Visit the ECIO website
previous arrow
next arrow
Slider

SIRT in four steps

Quirem Medical develops and commercializes radioactive microspheres based on Holmium-166 for Selective Internal Radiation Therapy (SIRT). Holmium-166 microspheres can be visualized and quantified to facilitate patient selection, therapy planning and treatment verification. Through our innovative Holmium-166 platform technology, we aim to empower physicians to further drive treatment outcome of unresectable liver cancer after SIRT in four simple steps:

SELECT

Select only those patients that are likely to benefit from SIRT. Use QuiremScout®,  a safe dose of holmium microspheres, to evaluate the biodistribution of particles prior to therapy in your patients.

PLAN

Use our software package Q-SuiteTM to calculate required treatment activity,  predict lung dose, and simulate the treatment with QuiremSpheres®

TREAT

Treat with QuiremSpheres®, the next-generation microspheres, indicated for treatment of unresectable liver tumors. Click here to learn what value QuiremSpheres® can bring to your clinic.

VERIFY

Use our software package Q-SuiteTM to determine SIRT succes right after the procedure, by evaluating the absorbed dose in the lesions and normal liver tissue

News and events

What our customers say

“With QuiremSpheres we see the majority of our patients responding much quicker than what we are used to seeing with Y-90. The lesions are already shrinking just 45 days post-procedure. In fact, two of our patients originally deemed to be non-surgical candidates had a resection and a transplant, respectively, after radioembolization with QuiremSpheres®.”
Dr. I. BargelliniInterventional Radiologist, University of Pisa
“The short halftime of holmium-166 in QuiremSpheres® results in a high initial dose rate. Therefore, we expect to see an improved radiobiological effect.”
Prof. KotzerkeHead Nuclear Medicine,
Universitätsklinikum Dresden
"QuiremScout® enables us to evaluate the safety and efficacy profile of SIRT, prior to the therapeutic procedure. We can now select and treat only those patients that are likely to benefit from SIRT."
Prof. Dr. Marnix G.E.H. Lam
Prof. Dr. Marnix G.E.H. LamHead of Nuclear Medicine,
University Medical Center Utrecht
“QuiremSpheres® gives us the confidence we need to start individualizing treatments.”​
Dr. Ralf-Thorsten Hoffmann​Interventional Radiologist at Uniklinikum Dresden
Previous
Next
logo

Zutphenseweg 55

7418AH Deventer

The Netherlands

Telephone: +31 85 0404170  

E-mail: info@quirem.com